Atrial Fibrillation Screening
Keywords:
atrial fibrillation, screening, stroke, preventionAbstract
Atrial fibrillation (AF) is the most common arrhythmia resulting in the burden of healthcare. Screening for AF can lead to stroke prevention with oral anticoagulants in selected patients. Opportunistic screening for AF should be performed in people aged ≥65 years by pulse palpation. Systematic screening for AF should be introduced in people aged ≥75 years or those at high risk for ischemic stroke. Patients with cardiac implantable electronic devices who have atrial high-rate episodes (AHREs) should be further investigated for the diagnosis of AF. Oral anticoagulant should be prescribed if AHREs ≥5.5 hours in patients with a high risk of ischemic stroke (CHA2DS2-VASc score >1 in males or >2 in females). AF screening following ischemic stroke should be done with pulse palpation and 12-lead electrocardiography, as well as ECG monitoring for 24-72 hours to increase the chance of detecting AF. The devices with new technologies are promising tools for AF screening with ease. Even though AF screening is cost-effective, higher costs for more investigation and treatment are often a concern after AF diagnosis. The appropriate strategy for AF screening in Thailand should be investigated for the cost-effectiveness.
Downloads
References
Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association [published correction appears in Circulation. 2020 Jan 14;141(2):e33]. Circulation. 2019;139(10):e56-e528. doi:10.1161/CIR.0000000000000659.
Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147(1):109-119. doi:10.1378/chest.14-0321.
Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy--pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J. 2015;79(2):432-438. doi:10.1253/circj.CJ-14-1131.
Ho CW, Ho MH, Chan PH, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke. 2015;46(1):23-30. doi:10.1161/STROKEAHA.114.006476.
Guo Y, Lip GY, Apostolakis S. The unmet need of stroke prevention in atrial fibrillation in the far East and South East Asia. Malays J Med Sci. 2012;19(3):1-7.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-00007.
Du X, Guo L, Xia S, et al. Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China. Heart. doi:10.1136/heartjnl-2020-317915
Kim D, Yang PS, Jang E, et al. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J. 2018;202:20-26. doi:10.1016/j.ahj.2018.04.017
Chao TF, Liu CJ, Tuan TC, et al. Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation: A Report From the Taiwan Nationwide AF Cohort Study. Chest. 2018;153(2):453-466. doi:10.1016/j.chest.2017.10.001
Phrommintikul A, Detnuntarat P, Prasertwitayakij N, Wongcharoen W. Prevalence of atrial fibrillation in Thai elderly. J Geriatr Cardiol. 2016;13(3):270-273. doi:10.11909/j.issn.1671-5411.2016.03.002
Suwanwela NC, Chutinet A, Autjimanon H, et al. Atrial fibrillation prevalence and risk profile from novel community-based screening in Thailand: A prospective multi-centre study. Int J Cardiol Heart Vasc. 2021;32:100709. doi:10.1016/j.ijcha.2020.100709.
Lee H, Kim TH, Baek YS, et al. The Trends of Atrial Fibrillation-Related Hospital Visit and Cost, Treatment Pattern and Mortality in Korea: 10-Year Nationwide Sample Cohort Data. Korean Circ J. 2017;47(1):56-64. doi:10.4070/kcj.2016.0045.
Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK [published correction appears in Heart. 2007 Nov;93(11):1472. Murphy, N [corrected to Murphy, N F]]. Heart. 2004;90(3):286-292. doi:10.1136/hrt.2002.008748.
Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313-320. doi:10.1161/CIRCOUTCOMES.110.958165.
Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol. 2004;44(6):1268-1275. doi:10.1016/j.jacc.2004.06.029.
Kim D, Yang PS, Jang E, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. Heart. 2018;104(24):2010-2017. doi:10.1136/heartjnl-2017-312930.
Gordis L, Lilienfeld A, Rodriguez R. Studies in the epidemiology and preventability of rheumatic fever. II. Socio-economic factors and the incidence of acute attacks. J Chronic Dis. 1969;21(9):655-666. doi:10.1016/0021-9681(69)90037-x.
Parkash R, Green MS, Kerr CR, et al. The association of left atrial size and occurrence of atrial fibrillation: a prospective cohort study from the Canadian Registry of Atrial Fibrillation. Am Heart J. 2004;148(4):649-654. doi:10.1016/j.ahj.2004.04.029.
Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J. 2015;36(18):1115-22a. doi:10.1093/eurheartj/ehu449.
Chan NY, Orchard J, Agbayani MJ, et al. 2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening. J Arrhythm. 2021;38(1):31-49.doi:10.1002/joa3.12669.
Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial [published correction appears in Lancet. 2021 Oct 23;398(10310):1486]. Lancet. 2021;398(10310):1507-1516. doi:10.1016/S0140-6736(21)01698-6.
Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet. 2021;398(10310):1498-1506. doi:10.1016/S0140-6736(21)01637-8.
Lowres N, Freedman B. Population screening for atrial fibrillation to prevent stroke [published correction appears in Lancet. 2021 Oct 23;398(10310):1486]. Lancet. 2021;398(10310):1463-1465. doi:10.1016/S0140-6736(21)01750-5.
Abolghasem Gorji H, Khosravi M, Mahmoodi R, et al. Cost-Effectiveness of Atrial Fibrillation Screening Strategies: A Systematic Review. Iran J Public Health. 2023;52(4):672-682. doi:10.18502/ijph.v52i4.12435.
Kawakami H, Nagai T, Saito M, et al. Clinical significance of atrial high-rate episodes for thromboembolic events in Japanese population. Heart Asia. 2017;9(2):e010954.doi:10.1136/heartasia-2017-010954.
Hohnloser SH, Capucci A, Fain E, et al. ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J. 2006;152(3):442-447. doi:10.1016/j.ahj.2006.02.016.
Mahajan R, Perera T, Elliott AD, et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J. 2018;39(16):1407-1415. doi:10.1093/eurheartj/ehx731.
Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2(5):474-480. doi:10.1161/CIRCEP.109.849638.
Perino AC, Fan J, Askari M, et al. Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation. Circulation. 2019;139(22):2502-2512. doi:10.1161/CIRCULATIONAHA.118.038988.
Daoud EG, Glotzer TV, Wyse DG, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm. 2011;8(9):1416-1423. doi:10.1016/j.hrthm.2011.04.022.
Ghandehari K, Izadi Z; Khorasan Stroke Registry. The Khorasan Stroke Registry: results of a five-year hospital-based study. Cerebrovasc Dis. 2007;23(2-3):132-139. doi:10.1159/000097050.
Negi PC, Sondhi S, Rana V, et al. Prevalence, risk determinants and consequences of atrial fibrillation in rheumatic heart disease: 6 years hospital based-Himachal Pradesh- Rheumatic Fever/Rheumatic Heart Disease (HP-RF/RHD) Registry. Indian Heart J. 2018;70 Suppl 3(Suppl 3):S68-S73. doi:10.1016/j.ihj.2018.05.013.
Diker E, Aydogdu S, Ozdemir M, et al. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. Am J Cardiol. 1996;77(1):96-98. doi:10.1016/s0002-9149(97)89145-x.
Henry WL, Morganroth J, Pearlman AS, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation. 1976;53(2):273-279. doi:10.1161/01.cir.53.2.273.
Sharma SK, Verma SH. A Clinical Evaluation of Atrial Fibrillation in Rheumatic Heart Disease. J Assoc Physicians India. 2015;63(6):22-25.
Acar J, Michel PL, Cormier B, Vahanian A, Iung B. Features of patients with severe mitral stenosis with respect to atrial rhythm. Atrial fibrillation in predominant and tight mitral stenosis. Acta Cardiol. 1992;47(2):115-124.
Kitchin A, Turner R. Calcification of the mitral valve. Results of valvotomy in 100 cases. Br Heart J. 1967;29(2):137-161. doi:10.1136/hrt.29.2.137.
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [published correction appears in Eur Heart J. 2021 Feb 1;42(5):507] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):546-547] [published correction appears in Eur Heart J. 2021 Oct .21;42(40):4194]. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.
Hobbs FD, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005;9(40):iii-74. doi:10.3310/hta9400.
Taggar JS, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: A systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(12):1330-1338. doi:10.1177/2047487315611347.
Cooke G, Doust J, Sanders S. Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. J Fam Pract. 2006;55(2):130-134.
Unit EI. Preventing stroke: uneven progress. A global policy research programme. The Economist. 2017;21:1-28.
Dörr M, Nohturfft V, Brasier N, et al. The WATCH AF Trial: SmartWATCHes for Detection of Atrial Fibrillation. JACC Clin Electrophysiol. 2019;5(2):199-208. doi:10.1016/j.jacep.2018.10.006.
Perera KS, Vanassche T, Bosch J, et al. Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke: Embolic Stroke of Undetermined Source Global Registry. Stroke. 2016;47(9):2197-2202. doi:10.1161/STROKEAHA.116.013378.
Tu HT, Campbell BC, Christensen S, et al. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation. Int J Stroke. 2015;10(4):534-540. doi:10.1111/ijs.12007.
Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol .2015;14:377-387.
Yan B, Tu H, Lam C, et al. Nurse Led Smartphone Electrographic Monitoring for Atrial Fibrillation after Ischemic Stroke: SPOT-AF. J Stroke. 2020;22(3):387-395. doi:10.5853/jos.2020.00689.
Tu HT, Chen Z, Swift C, et al. Smartphone electrographic monitoring for atrial fibrillation in acute ischemic stroke and transient ischemic attack. Int J Stroke. 2017;12(7):786-789. doi:10.1177/1747493017696097.
Orchard J, Li J, Freedman B, et al. Atrial Fibrillation Screen, Management, and Guideline-Recommended Therapy in the Rural Primary Care Setting: A Cross-Sectional Study and Cost-Effectiveness Analysis of eHealth Tools to Support All Stages of Screening. J Am Heart Assoc. 2020;9(18):e017080. doi:10.1161/JAHA.120.017080.
Jacobs MS, Kaasenbrood F, Postma MJ, van Hulst M, Tieleman RG. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace. 2018;20(1):12-18. doi:10.1093/europace/euw285.
Chan NY, Choy CC, Chan CK, Siu CW. Effectiveness of a nongovernmental organization-led large-scale community atrial fibrillation screening program using the smartphone electrocardiogram: An observational cohort study. Heart Rhythm. 2018;15(9):1306-1311. doi:10.1016/j.hrthm.2018.06.006.
Svennberg E, Stridh M, Engdahl J, et al. Safe automatic one-lead electrocardiogram analysis in screening for atrial fibrillation. Europace. 2017;19(9):1449-1453. doi:10.1093/europace/euw286.
Tieleman RG, Plantinga Y, Rinkes D, et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace. 2014;16(9):1291-1295. doi:10.1093/europace/euu057.
Vaes B, Stalpaert S, Tavernier K, et al. The diagnostic accuracy of the MyDiagnostick to detect atrial fibrillation in primary care. BMC Fam Pract. 2014;15:113. doi:10.1186/1471-2296-15-113.
Kearley K, Selwood M, Van den Bruel A, et al. Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors. BMJ Open. 2014;4(5):e004565.doi:10.1136/bmjopen-2013-004565.
Bumgarner JM, Lambert CT, Hussein AA, et al. Smartwatch Algorithm for Automated Detection of Atrial Fibrillation. J Am Coll Cardiol. 2018;71(21):2381-2388. doi:10.1016/j.jacc.2018.03.003.
Chan PH, Wong CK, Pun L, et al. Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting. BMJ Open. 2017;7(6):e013685. doi:10.1136/bmjopen-2016-013685.
Marazzi G, Iellamo F, Volterrani M, et al. Comparison of Microlife BP A200 Plus and Omron M6 blood pressure monitors to detect atrial fibrillation in hypertensive patients [published correction appears in Adv Ther. 2014 Dec;31(12):1317]. Adv Ther. 2012;29(1):64-70. doi:10.1007/s12325-011-0087-0.
Wiesel J, Arbesfeld B, Schechter D. Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. Am J Cardiol. 2014;114(7):1046-1048. doi:10.1016/j.amjcard.2014.07.016.
McMANUS DD, Chong JW, Soni A, et al. PULSE-SMART: Pulse-Based Arrhythmia Discrimination Using a Novel Smartphone Application. J Cardiovasc Electrophysiol. 2016;27(1):51-57. doi:10.1111/jce.12842.
Chan PH, Wong CK, Poh YC, et al. Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting. J Am Heart Assoc. 2016;5(7):e003428.doi:10.1161/ JAHA.116.003428.
Yan BP, Lai WHS, Chan CKY, et al. Contact-Free Screening of Atrial Fibrillation by a Smartphone Using Facial Pulsatile Photoplethysmographic Signals. J Am Heart Assoc. 2018;7(8):e008585.doi:10.1161/JAHA.118.008585.
Kwon S, Hong J, Choi EK, et al. Detection of Atrial Fibrillation Using a Ring-Type Wearable Device (CardioTracker) and Deep Learning Analysis of Photoplethysmography Signals: Prospective Observational Proof-of-Concept Study. J Med Internet Res. 2020;22(5):e16443.doi:10.2196/16443.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Chulabhorn Royal Academy
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของราชวิทยาลัยจุฬาภรณ์
ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับราชวิทยาลัยจุฬาภรณ์ และคณาจารย์ท่านอื่น ในราชวิทยาลัยฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใด ๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
